Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that can lead to cirrhosis, liver transplant, and even hepatocellular carcinoma. While liver biopsy remains the reference standard for disease diagnosis, analytical and clinical development of non-invasive soluble biomarkers of NASH are...
Main Authors: | Sumit Kar, Sabina Paglialunga, Sharon H Jaycox, Rafiqul Islam, Angelo H Paredes |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0217263 |
Similar Items
-
Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
by: Weiguo Fan, et al.
Published: (2021-04-01) -
Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
by: Michael Ogundele, et al.
Published: (2021-08-01) -
DNA methylation of SMPD3-based diagnostic biomarkers of NASH and mild fibrosis
by: Na Wu, et al.
Published: (2024-01-01) -
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
by: Yi Luo, et al.
Published: (2021-05-01) -
Identification and validation of chemokine system-related genes in idiopathic pulmonary fibrosis
by: Tianming Zhao, et al.
Published: (2023-04-01)